Raphael Mohr

Charité - Universitätsmedizin Berlin

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (16)

Uwe Pelzer

GERMANY

View details

Wolfgang Boehmerle

Charite Universitatsmedizin Berlin Klinik für Neurologie mit Experimenteller Neurologie

GERMANY

View details

Michael Sigal

Professor for Translational Gastrointestinal Oncology

Charité - Universitätsmedizin Berlin

GERMANY

View details

Werner Stenzel

Head of Neuromuscular Diagnostic and Research unit/ Professor Dr. med.

Charité - Universitätsmedizin Berlin

GERMANY

View details

Tobias Puengel

Charité - Universitätsmedizin Berlin

GERMANY

View details

Nikolaj Frost

Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum

GERMANY

View details

Dominik Geisel

Charité

GERMANY

View details

Wenzel Schöning

Charité - Universitätsmedizin Berlin

GERMANY

View details

Bernhard Gebauer

Charité - Universitätsmedizin Berlin

GERMANY

View details

Samuel Knauss

GERMANY

View details

Stefan Frischbutter

Head of Basic Science

Charité Universitätsmedizin Berlin Campus Benjamin Franklin

GERMANY

View details

Felix Krenzien

GERMANY

View details

Uli Fehrenbach

Charité - Universitätsmedizin Berlin

GERMANY

View details

Thula Cannon Walter-Rittel

GERMANY

View details

Frank Tacke

GERMANY

View details

Alexander Wree

Charité - Universitätsmedizin Berlin

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Raphael Mohr

Research Interests

Explore related searches

Contact this professor

Articles (24)

CT-guided high-dose-rate brachytherapy ablation of HCC patients with portal vein tumor thrombosis.

HLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis

Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma

Development of Liver‐Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging

miR-223 and Chromogranin A Affect Inflammatory Immune Cell Activation in Liver Metastasis of Neuroendocrine Neoplasms

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.

Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma.

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population.

Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events.

Extracellular NAD+ response to post-hepatectomy liver failure: bridging preclinical and clinical findings

Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply

Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS

Extracellular Vesicles May Predict Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma

Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma.

Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms.

Prediction of regional lymph node metastasis in intrahepatic cholangiocarcinoma: it's not all about size.

Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma—State of the Art and Future Perspectives

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort

Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients.

Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art.

Prevalence of and factors associated with a treatment delay due to the COVID-19 pandemic in patients with gastrointestinal cancer in Europe.

Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity

Collaborators (16)

Uwe Pelzer

Wolfgang Boehmerle

Michael Sigal

Werner Stenzel

Tobias Puengel

Nikolaj Frost

Dominik Geisel

Wenzel Schöning

Bernhard Gebauer

Samuel Knauss

Stefan Frischbutter

Felix Krenzien

Uli Fehrenbach

Thula Cannon Walter-Rittel

Frank Tacke

Alexander Wree

Make your next move.

HLA-A01:01-B08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis